Under President Trump, DHS Blocks Chinese Genomics Companies Linked to Forced Labor

DHS enforcement action advances President Trump's commitment to enforcing trade laws, keeping goods tied to forced labor and mass surveillance out of U.S. supply chains, and protecting American workers and businesses from unfair competition

WASHINGTON - Today, the Department of Homeland Security (DHS), on behalf of the Forced Labor Enforcement Task Force (FLETF), announced the addition of three Chinese companies to the Uyghur Forced Labor Prevention Act (UFLPA) Entity List. The action means goods made by these companies are prohibited from entering the United States unless the importer can demonstrate, under the law's requirements, that the goods were not made with forced labor.

The FLETF determined that these three affiliated Chinese genomics companies help the government of the Xinjiang Uyghur Autonomous Region, a region in northwest China known as Xinjiang, build and operate its mass surveillance infrastructure. The system uses data, derived from genetic material, and other information to monitor ethnic minorities and supports the government's broader repression, including labor-transfer programs and internment, often conducted under the guise of "healthcare." Together, the companies constitute one of the largest advanced gene-sequencing and genetic-material collection enterprises in the world.

"Under President Trump's leadership, we are not going to let companies tied to forced labor and the surveillance of persecuted minorities profit from the American market," saidHomeland Security Secretary Markwayne Mullin. "Today, DHS is barring three Chinese DNA testing companies from allowing their goods to enter the United States unless importers can meet the law's requirements. This is about enforcing our laws, protecting American businesses from unfair competition, and making clear that companies connected to forced labor will not get a free pass in this country."

The Trump Administration is setting high standards for protecting workers at home and abroad by taking tough action to root out forced labor from global supply chains. With today's announcement, the UFLPA Entity List includes 190 entities. This follows DHS's July 31, 2026, announcement adding 43 entities to the list, the largest single expansion since the list was created.

"These companies' behavior shows an unwillingness to separate profit motives from basic codes of human dignity," said DHS Under Secretary for Strategy, Policy, & Plans Rob Law, who serves as the Chair of the Forced Labor Enforcement Task Force."Today, we're taking action to realign those motives - at least as far as the U.S. market is concerned - goods produced by these companies will not be allowed entry unless they can prove that they do not take part in the forced labor apparatus in Xinjiang."

Effective October 29, 2026, U.S. Customs and Border Protection (CBP) will apply a rebuttable presumption that goods produced by these three entities are prohibited from entering the United States as a result of the companies' activities, either sourcing materials from the Xinjiang Uyghur Autonomous Region (Xinjiang, the XUAR) or working with the government of Xinjiang to recruit, transport, transfer, harbor, or receive forced labor or Uyghurs, Kazakhs, Kyrgyz, or members of other persecuted groups out of Xinjiang.

Credible information, including corporate and government reporting, indicates that all three entities support genetic testing in the XUAR alongside the XUAR government and as a part of its government initiatives. The collection and analysis of genetic material facilitate the monitoring, surveillance, and repression of ethnic minorities by the government of the People's Republic of China, including the abhorrent practice of forced labor.

Today's action also advances the Trump Administration's broader work to enforce U.S. trade laws and combat trade fraud. Ensuring that malign actors are held fully accountable for violations of U.S. customs and trade laws, including the UFLPA, is a key mandate of the joint DHS and DOJ Trade Fraud Task Force, which has realized over $1 billion in penalties, recoveries, and charged losses in its first year of operation.

"The DHS-DOJ Trade Fraud Task Force will be watching for anyone attempting to circumvent today's action, and will prosecute them to the fullest extent," said DHS Assistant Secretary for Trade and Economic Security Aris Kourkoumelis. "Members of the trade community need to understand our resolve and the significant consequences coming for those that would seek to violate the law."

DHS and the FLETF continue to work closely with stakeholders across industry, mission-driven organizations, and international partners to strengthen enforcement and support compliance. Addressing these threats strengthens global supply chains and our economic and national security. Additions to the UFLPA Entity List assist CBP in its enforcement and help eliminate threats to American businesses from foreign competitors' unfair practices.

DHS has published the revised UFLPA Entity List as an appendix to a Federal Register notice.

Read more about DHS's implementation and enforcement of the UFLPA by visiting www.dhs.gov/uflpa .

Entity-Specific Information

The three entities added to the UFLPA Entity List are related companies. Shenzhen BGI Technology Co., Ltd. (BGI Group) is the controlling shareholder of BGI Genomics Co., Ltd. MGI Tech Co., Ltd. is under the control of the same ultimate controlling shareholder as BGI Group. All three entities met the criteria for inclusion to the UFLPA Entity List under section 2(d)(2)(B)(ii) of the UFLPA, and two of the companies have also met the criteria for inclusion under section 2(d)(2)(B)(v) of the UFLPA.

Additions to the UFLPA Entity List under section 2(d)(2)(B)(ii):

The FLETF has added three (3) entities to the UFLPA Entity List under section 2(d)(2)(B)(ii) of the UFLPA, which identifies entities working with the government of Xinjiang to recruit, transport, transfer, harbor, or receive forced labor or Uyghurs, Kazakhs, Kyrgyz, or members of other persecuted groups out of Xinjiang:

• BGI Genomics Co., Ltd. (also known as BGI Genomics)
• MGI Tech Co., Ltd. (also known as MGI)
• Shenzhen BGI Technology Co., Ltd. (also known as BGI Group; and BGI Holdings)

BGI Genomics Co., Ltd.

BGI Genomics Co., Ltd. (also known as BGI Genomics) is located in Shenzhen, Guangdong Province, China. Shenzhen BGI Technology Co., Ltd., also included on the UFLPA Entity List, is the company's controlling shareholder. BGI Genomics' main business includes providing research services, comprehensive solutions for precision medicine testing, and health management services through gene testing, mass spectrometry, bioinformatics analysis, and multimodal intelligent analysis models. The United States Government has reasonable cause to believe, based on specific and articulable information, that BGI Genomics conducts genetic testing in the XUAR alongside the government of the XUAR and as a part of its government initiatives. Such genetic testing is utilized to facilitate the recruitment, transport, transfer, harboring or receiving of forced labor. Information reviewed by the FLETF, including Chinese government and publicly available information, indicates that BGI Genomics works with the government of the XUAR to transport, transfer, harbor, or receive forced labor or Uyghurs Kazakhs, Kyrgyz, or members of other persecuted groups out of Xinjiang. The FLETF therefore determined the activities of BGI Genomics satisfy the criterion for addition to the UFLPA Entity List described in section 2(d)(2)(B)(ii).

MGI Tech Co., Ltd.

MGI Tech Co., Ltd. (also known as MGI) is located in Shenzhen, Guangdong Province, China. MGI is under the control of the same ultimate controlling shareholder as Shenzhen BGI Technology Co., Ltd., also included on the UFLPA Entity List. MGI's business activities focus on the research and development, manufacturing, and sales of instruments, reagents, and related products in the field of life science and biotechnology. The United States Government has reasonable cause to believe, based on specific and articulable information, that MGI has provisioned genetic testing capacity to the XUAR government to genetic testing in the XUAR including as a part of its government initiatives. Such genetic testing is utilized to facilitate recruitment, transport, transfer, harboring or receiving of forced labor or Uyghurs, Kazakhs, Kyrgyz, or members of other persecuted groups out of Xinjiang. Information reviewed by the FLETF, including Chinese government and publicly available information, indicates that MGI works with the government of the XUAR to transport, transfer, harbor, or receive forced labor or Uyghurs, Kazakhs, Kyrgyz, or members of other persecuted groups out of Xinjiang. The FLETF therefore determined the activities of MGI satisfy the criterion for addition to the UFLPA Entity List described in section 2(d)(2)(B)(ii).

Shenzhen BGI Technology Co., Ltd.

Shenzhen BGI Technology Co., Ltd. (also known as BGI Group; and BGI Holdings) is a company located in Shenzhen, Guangdong Province, China. BGI Group is a genomics and biotechnology company that develops and applies genetic sequencing technologies for research, healthcare, and commercial use. It provides DNA, RNA, and metabolomics sequencing technology and can provide services, as well as equipment, technical support, and precision medicine and health solutions. The company also built and manages the China National GeneBank, a national-level biological data and sample repository. The United States Government has reasonable cause to believe, based on specific and articulable information, that BGI Group conduct genetic testing in the XUAR alongside the XUAR government and as a part of its government initiatives. Such genetic testing is utilized to facilitate the recruitment, transport, transfer, harboring or receiving of forced labor. Information reviewed by the FLETF, including Chinese government and publicly available information, indicates that BGI Group works with the government of the XUAR to transport, transfer, harbor, or receive forced labor or Uyghurs, Kazakhs, Kyrgyz, or members of other persecuted groups out of Xinjiang. The FLETF therefore determined the activities of BGI Group satisfy the criterion for addition to the UFLPA Entity List described in section 2(d)(2)(B)(ii).

Additions to the UFLPA Entity List under section 2(d)(2)(B)(v):

The FLETF also added two (2) entities to the UFLPA Entity List under section 2(d)(2)(B)(v) of the UFLPA, which identifies facilities and entities that source material from Xinjiang or from persons working with the government of Xinjiang or the Xinjiang Production and Construction Corps for purposes of the "poverty alleviation" program or the "pairing-assistance" program or any other government labor scheme that uses forced labor:

• BGI Genomics Co., Ltd. (also known as BGI Genomics)
• Shenzhen BGI Technology Co., Ltd. (also known as BGI Group; and BGI Holdings)

BGI Genomics Co., Ltd.

BGI Genomics Co., Ltd. (also known as BGI Genomics) is located in Shenzhen, Guangdong Province, China. Shenzhen BGI Technology Co., Ltd., also included on the UFLPA Entity List, is the company's controlling shareholder. BGI Genomics' main business includes providing research services, comprehensive solutions for precision medicine testing, and health management services through gene testing, mass spectrometry, bioinformatics analysis, and multimodal intelligent analysis models. The United States Government has reasonable cause to believe, based on specific and articulable information, that BGI Genomics conducts genetic testing, including on genetic material of plants, animals, and bacterial diseases sourced from the XUAR. Information reviewed by the FLETF, including research papers and publicly available information, indicates that BGI Genomics sources genetic material from the XUAR. The FLETF therefore determined the activities of BGI Genomics satisfy the criterion for addition to the UFLPA Entity List described in section 2(d)(2)(B)(v).

Shenzhen BGI Technology Co., Ltd.

Shenzhen BGI Technology Co., Ltd. (also known as BGI Group; and BGI Holdings) is a company located in Shenzhen, Guangdong Province, China. BGI Group is a genomics and biotechnology company that develops and applies genetic sequencing technologies for research, healthcare, and commercial use. It provides DNA, RNA, and metabolomics sequencing technology and can provide services, as well as equipment, technical support, and precision medicine and health solutions. The company also built and manages the China National GeneBank, a national-level biological data and sample repository. The United States Government has reasonable cause to believe, based on specific and articulable information, that BGI Group conduct genetic testing, including on genetic material of human beings sourced from the XUAR, as well as planning on testing genetic materials of plants and animals. Information reviewed by the FLETF, including Chinese government and publicly available information, indicates that BGI Group sources genetic material from the XUAR. The FLETF therefore determined the activities of BGI Group satisfy the criterion for addition to the UFLPA Entity List described in section 2(d)(2)(B)(v).